Methotrexate-induced Nausea in the Treatment of Juvenile Idiopathic Arthritis

Overview

Journal Pediatr Rheumatol Online J

Publisher Biomed Central

Specialty Pediatrics

Date 2017 Jun 21

PMID 28629458

Citations 11

Authors

Sonja Falvey

Lauren Shipman

Norman Ilowite

Timothy Beukelman

Affiliations

Soon will be listed here.

Abstract

Background: Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients.

Main Body: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach.

Conclusion: Understanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.

Citing Articles

Development and Delivery of an Integrated Digital Health Care Approach for Children With Juvenile Idiopathic Arthritis: Usability Study.

Butler S, Sculley D, Santos D, Girones X, Singh-Grewal D, Coda A JMIR Pediatr Parent. 2024; 7:e56816.

PMID: 39287603 PMC: 11421306. DOI: 10.2196/56816.

International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector.

Muller-Ladner U, Edwards C, Erkens A Patient Prefer Adherence. 2024; 18:579-590.

PMID: 38463400 PMC: 10924829. DOI: 10.2147/PPA.S440818.

Evaluation of Methotrexate Intolerance in Children With Morphea.

McColl J, Laxer R, Pope E, Sibbald C J Pediatr Pharmacol Ther. 2023; 28(6):559-564.

PMID: 38130351 PMC: 10731950. DOI: 10.5863/1551-6776-28.6.559.

Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis.

Case S, Nigrovic P Paediatr Drugs. 2022; 24(3):185-191.

PMID: 35364780 PMC: 10389810. DOI: 10.1007/s40272-022-00496-0.

Dental caries in children and adolescents with juvenile idiopathic arthritis and controls: a multilevel analysis.

Gil E, Astrom A, Lie S, Rygg M, Fischer J, Rosen A BMC Oral Health. 2021; 21(1):417.

PMID: 34433437 PMC: 8390188. DOI: 10.1186/s12903-021-01758-y.

References

Van Dijkhuizen E, Bulatovic Calasan M, Pluijm S, de Rotte M, Vastert S, Kamphuis S . Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. Pediatr Rheumatol Online J. 2015; 13:5. PMC: 4349799. DOI: 10.1186/s12969-015-0002-3. View

Ruperto N, Murray K, Gerloni V, Wulffraat N, Knupp Feitosa de Oliveira S, Falcini F . A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50(7):2191-201. DOI: 10.1002/art.20288. View

Culy C, Bhana N, Plosker G . Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs. 2001; 3(6):441-79. DOI: 10.2165/00128072-200103060-00007. View

Shea B, Swinden M, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T . Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013; (5):CD000951. PMC: 7046011. DOI: 10.1002/14651858.CD000951.pub2. View

Woo P, Southwood T, Prieur A, Dore C, Grainger J, David J . Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43(8):1849-57. DOI: 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F. View

Alsufyani K, Ortiz-Alvarez O, Cabral D, Tucker L, Petty R, Malleson P . The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004; 31(1):179-82. View

Hashkes P, Becker M, Cabral D, Laxer R, Paller A, Rabinovich C . Methotrexate: new uses for an old drug. J Pediatr. 2013; 164(2):231-6. DOI: 10.1016/j.jpeds.2013.10.029. View

van der Meer A, Wulffraat N, Prakken B, Gijsbers B, Rademaker C, Sinnema G . Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007; 25(3):480-5. View

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F . Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. Int J Rheumatol. 2011; 2011:845496. PMC: 3228304. DOI: 10.1155/2011/845496. View

10.

Silverman E, Mouy R, Spiegel L, Jung L, Saurenmann R, Lahdenne P . Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005; 352(16):1655-66. DOI: 10.1056/NEJMoa041810. View

11.

Mulligan K, Kassoumeri L, Etheridge A, Moncrieffe H, Wedderburn L, Newman S . Mothers' reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life. Pediatr Rheumatol Online J. 2013; 11(1):23. PMC: 3679741. DOI: 10.1186/1546-0096-11-23. View

12.

Blanco R, Gonzalez-Gay M, Garcia-Porrua C, Ibanez D, Garcia-Pais M, Sanchez-Andrade A . Ondansetron prevents refractory and severe methotrexate-induced nausea in rheumatoid arthritis. Br J Rheumatol. 1998; 37(5):590-2. DOI: 10.1093/rheumatology/37.5.590. View

13.

Kempinska A, Benchimol E, Mack A, Barkey J, Boland M, Mack D . Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2011; 53(4):389-93. DOI: 10.1097/MPG.0b013e31822855e7. View

14.

Foeldvari I, Wierk A . Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol. 2010; 37(8):1763-7. DOI: 10.3899/jrheum.090874. View

15.

Brunner H, Johnson A, Barron A, Passo M, Griffin T, Graham T . Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol. 2005; 11(4):194-204. DOI: 10.1097/01.rhu.0000173616.81928.44. View

16.

Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G . Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012; 64(9):1349-56. DOI: 10.1002/acr.21697. View

17.

Petty R, Southwood T, Manners P, Baum J, Glass D, Goldenberg J . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2):390-2. View

18.

Fedorowicz Z, Jagannath V, Carter B . Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011; (9):CD005506. PMC: 6768985. DOI: 10.1002/14651858.CD005506.pub5. View

19.

Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A . Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999; 17(5):625-7. View

20.

Mannion M, Xie F, Curtis J, Beukelman T . Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors. J Rheumatol. 2014; 41(10):2078-84. DOI: 10.3899/jrheum.140012. View